Chairman of the Board of Directors and Chief Execu
United States of America
Daniel Zurr Ph.D., CEO, Founder and Chairman of the Board. Dr. Zurr also serves as a Director of QBI, a wholly-owned subsidiary of Quark Pharmaceuticals. Dr. Zurr has extensive experience in senior research and business management in the chemical and pharmaceutical industries. Prior to establishing Quark, Dr. Zurr was the CEO of Plantex-Ikapharm, then the second largest pharmaceutical company in Israel with more than 300 employees and marketing offices in the United States, Europe and Japan, focused in the field of bulk active ingredients and finished dosage pharmaceuticals. During Dr. Zurr’s tenure, Plantex Ikapharm, now part of the Teva group of companies, became the first Israeli company ever to be inspected and found to be in compliance with US standards for GMP. In the early 1980s, Dr. Zurr served as the Director of Licensing at G.D. Searle in Skokie, Illinois, where he was responsible for the major collaborative agreement between G.D. Searle and Meiji Seika Kaisha (Tokyo), involving the licensing of several drugs and recombinant DNA technology transfer. Dr. Zurr was also responsible for numerous other agreements, including those with Bayer AG (Leverkusen), Ono Pharmaceutical (Osaka) and May and Baker (London).
Dr. Zurr received his M.Sc. at the Hebrew University of Jerusalem and his Ph.D. from the Imperial College University of London under the guidance of the Nobel Laureate Professor D.H.R. Barton.